Springworks Therapeutics, Inc. (SWTX)
Stock Price:
$37.40 USD
1.26 (3.49%)
Updated Jul 14, 2020 12:32 PM EDT - Market open
Key Info
| Market Cap |
1.61B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
43.00M |
| EPS (ttm) |
-13.84 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 14, 2020 |
| Last Price |
$37.40 |
| Previous Close |
$36.14 |
| Change ($) |
1.26 |
| Change (%) |
3.49% |
| Day's Open |
36.25 |
| Day's Range |
35.28 - 37.67 |
| Day's Volume |
95,540 |
| 52-Week Range |
17.02 - 49.79 |
More Stats
| Market Cap |
1.61B |
| Enterprise Value |
1.30B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
43.00M |
| Float |
15.70M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-13.84 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.65M |
| Short Ratio |
7.13 |
| Short % of Float |
22.45% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.32 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
311.64M |
| Net Cash / Share |
7.25 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-15.55% |
| ROE |
-35.37% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$52.20*
(39.57% upside)
Low
48.0
Current: 37.40
High
58.0
Target: 52.20
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -59.24 | -18.49 |
| Net Income | -58.31 | -17.81 |
| Shares Outstanding | 43.01 | 341 |
| Earnings Per Share | -3.81 | - |
| Operating Cash Flow | -47.44 | -14.17 |
| Capital Expenditures | -0.67 | -0.29 |
| Free Cash Flow | -48.11 | -14.46 |
| Cash & Equivalents | 328 | 46.19 |
| Net Cash / Debt | 328 | 46.19 |
| Assets | 335 | 48.39 |
| Liabilities | 12.76 | 4.83 |
| Book Value | 322 | -19.37 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Springworks Therapeutics, Inc. |
| Country |
United States |
| Employees |
60 |
| CEO |
Saqib Islam |
Stock Information
| Ticker Symbol |
SWTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SWTX |
| IPO Date |
June 5, 1987 |
Description
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase IIb clinical trial for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in preclinical trials for the treatment of RRMM. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase Ib clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.